PL422094A1 - Molecule of nucleic acid, expression cartridge, expression vector, eukaryotic host cell, transgenic mammal, method for inducing RNA interference in eukaryotic host and application of a molecule of nucleic acid in the therapy of diseased induced by CAG-type trinucleotide repeat expansion - Google Patents
Molecule of nucleic acid, expression cartridge, expression vector, eukaryotic host cell, transgenic mammal, method for inducing RNA interference in eukaryotic host and application of a molecule of nucleic acid in the therapy of diseased induced by CAG-type trinucleotide repeat expansionInfo
- Publication number
- PL422094A1 PL422094A1 PL422094A PL42209413A PL422094A1 PL 422094 A1 PL422094 A1 PL 422094A1 PL 422094 A PL422094 A PL 422094A PL 42209413 A PL42209413 A PL 42209413A PL 422094 A1 PL422094 A1 PL 422094A1
- Authority
- PL
- Poland
- Prior art keywords
- nucleic acid
- eukaryotic host
- molecule
- cag
- rna interference
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 title abstract 3
- 230000009368 gene silencing by RNA Effects 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000009261 transgenic effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Przedmiotami wynalazku są Cząsteczka kwasu nukleinowego, kaseta ekspresyjna, wektor ekspresyjny, komórka eukariotycznego gospodarza, transgeniczny ssak, sposób indukowania interferencji RNA w eukariotycznym gospodarzu i zastosowanie cząsteczki kwasu nukleinowego w terapii chorób wywoływanych ekspansją trójnukleotydowych powtórzeń typu CAG. Rozwiązanie dotyczy nowej koncepcji leczenia dziedzicznych chorób neurologicznych człowieka wywoływanych ekspansją powtórzeń trójnukleotydowych typu CAG, z wykorzystaniem technologii interferencji RNA.The objects of the invention are a nucleic acid molecule, an expression cassette, an expression vector, a eukaryotic host cell, a transgenic mammal, a method of inducing RNA interference in a eukaryotic host, and the use of a nucleic acid molecule in the treatment of diseases caused by the expansion of CAG-like triucleotide repeats. The solution concerns a new concept for the treatment of hereditary human neurological diseases caused by the expansion of CAG-type three-nucleotide repeats using RNA interference technology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL422094A PL243777B1 (en) | 2013-09-02 | 2013-09-02 | Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell and the use of a nucleic acid molecule in the therapy of diseases caused by the expansion of trinucleotide repeats of the CAG type |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL422094A PL243777B1 (en) | 2013-09-02 | 2013-09-02 | Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell and the use of a nucleic acid molecule in the therapy of diseases caused by the expansion of trinucleotide repeats of the CAG type |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL422094A1 true PL422094A1 (en) | 2017-10-09 |
| PL243777B1 PL243777B1 (en) | 2023-10-09 |
Family
ID=59996986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL422094A PL243777B1 (en) | 2013-09-02 | 2013-09-02 | Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell and the use of a nucleic acid molecule in the therapy of diseases caused by the expansion of trinucleotide repeats of the CAG type |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL243777B1 (en) |
-
2013
- 2013-09-02 PL PL422094A patent/PL243777B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL243777B1 (en) | 2023-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124168T1 (en) | HETEROCYLLAMINES AS PI3K INHIBITORS | |
| PL3858333T3 (en) | PRODUCTION AND STORAGE OF LIPOSOMAL RNA PREPARATIONS SUITABLE FOR THERAPY | |
| CY1122707T1 (en) | HETEROCYCLIC GLUTAMINASE INHIBITORS | |
| CY1124407T1 (en) | AUTOTAXIN INHIBITOR COMPOUNDS | |
| IL279918A (en) | Gene therapy vectors for the treatment of Danon disease | |
| CY1123485T1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
| IL262361B1 (en) | Preparations and methods for cell programming using targeted nucleic acid nanocarriers | |
| EP3468356A4 (en) | GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF DISEASES | |
| PT3313991T (en) | MODIFIED FACTOR IX AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS AND TISSUES | |
| IL272081A (en) | Photodynamic therapy method for skin problems | |
| MX381890B (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL285238A (en) | Gene therapy vectors for the treatment of Danon disease | |
| CY1123216T1 (en) | GLS1 INHIBITORS FOR THE TREATMENT OF DISEASE | |
| EA201500207A1 (en) | HETEROAROMATIC COMPOUNDS AS VTK INHIBITORS | |
| HUE055002T2 (en) | Nucleic Acid Constructs and Gene Therapy Vectors for Use in the Treatment of Wilson's Disease | |
| BR112015023659A2 (en) | controller and flexible coils for administration therapy such as cancer therapy | |
| HUE036000T2 (en) | Combination therapy for the treatment of cancer involving Claudin 18.2 antibodies | |
| MX383590B (en) | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASES. | |
| UY37379A (en) | DERIVATIVES OF N- (PIRIDIN-2-IL) PIRIDINA-SULFONAMIDE AND ITS USE IN THE TREATMENT OF DISEASES | |
| EP3556368A4 (en) | ONYCHOMYCOSIS THERAPEUTIC AGENT | |
| EA201591706A1 (en) | SALTED FORMS (S) -CHINUCLIDIN-3-IL- (2- (2- (4-Fluoro-phenyl) TIAZOL-4-IL) PROPAN-2-IL) CARBAMATE | |
| EP3750553A4 (en) | PSORIASIS THERAPEUTIC AGENT | |
| EA201591543A1 (en) | COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS | |
| IL277695B1 (en) | Palladianolide history as spliceosome targeting agents for cancer therapy | |
| CY1120084T1 (en) | Oligonucleotide for the regulation of gene expression and their uses |